Compare BUSE & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUSE | TYRA |
|---|---|---|
| Founded | 1868 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 1996 | 2021 |
| Metric | BUSE | TYRA |
|---|---|---|
| Price | $31.28 | $32.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $27.17 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 881.7K | 542.1K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $719,584,000.00 | N/A |
| Revenue This Year | $23.84 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | $60.13 | ★ N/A |
| Revenue Growth | ★ 55.66 | N/A |
| 52 Week Low | $21.96 | $9.96 |
| 52 Week High | $31.44 | $40.65 |
| Indicator | BUSE | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 68.12 | 53.50 |
| Support Level | $23.75 | $29.69 |
| Resistance Level | N/A | $33.38 |
| Average True Range (ATR) | 0.64 | 1.71 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 99.15 | 58.21 |
First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.